Inoviq Ltd has released a press release.
Outstanding SubB2M Ovarian Cancer Test Data
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Inoviq
- AGM & CEO Presentations and Chairmans Transcript
- BARD1 Gains New High-volume Customer for its hTERT Test
- Successful BARD1 Kit Evaluation
- BARD1 Awarded BTB Funding to Develop Breast Cancer Test
- Appendix 4E and Annual Report to Shareholders
Later from Inoviq
- Excellent SubB2M Breast Cancer Test Data
- Commencement of Legal Proceedings Against BARD1
- Appendix 4D and Half-year financial report
- Positive Results Evaluation of EXO-NET in Pancreatic Cancer
- BARD1 Signs Option Agreement for Type 3C Diabetes Test
Follow Inoviq into a list and get an email when it puts out news.
Follow Inoviq